Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
By Chris Wack
Entasis Therapeutics Holdings Inc. shares were up 8% to $1.80 Tuesday after the company said in a filing that Innoviva Inc. raised its non-binding offer to buy Entasis to $2 a share in cash.
The company said all other terms of the offer, originally made Feb. 2, remain unchanged.
Innoviva said it has been in continued discussion with Entasis management, and the new offer represents a 36% premium from Entasis' closing price of $1.47 on Jan. 31. The original offer was $1.80 a share in cash.
Innoviva said it provided $15 million to Entasis to hope the company evaluate the buyout proposal, and it doesn't intend to offer any long-term financing, as Entasis has requested.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 15, 2022 09:37 ET (13:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Story ID: 20220315DN006141
http://inva.com/about/
MAY 2021
Innoviva announced strategic repurchase of GSK’s equity stake
http://inva.com/team/
Pavel Raifeld
Chief Executive Officer
Pavel Raifeld, CFA, joined Innoviva as Chief Executive Officer in May 2020. Prior to that, Mr. Raifeld served on the investment team at Sarissa Capital Management LP, an investment management firm focused on improving strategies of companies to enhance shareholder value. Earlier, he was a senior member of the healthcare investment banking team at Credit Suisse. Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey & Company and The Boston Consulting Group. Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.
Board of Directors
Deborah L. Birx, M.D
Deborah L. Birx, M.D., has served as a member of our Board of Directors since March 2021. She is currently a member of our Audit Committee and our Nominating/Corporate Governance Committee. Dr. Birx is a world renowned medical expert and leader who most recently served as the response coordinator of the White House Coronavirus Task Force. Previously, she served as Ambassador-at-Large, when she assumed the role of the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy. Dr. Birx also served as the U.S. Global AIDS Coordinator where she oversaw the President’s Emergency Plan for AIDS Relief (PEPFAR) at the CDC and as the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research. From 1980 until 2008, Dr. Birx served in the United States Army, retiring with the rank of colonel. Dr. Birx has published over 230 manuscripts in peer-reviewed journals, authored nearly a dozen chapters in scientific publications, as well as developed and patented vaccines. She received her medical degree from the Hershey School of Medicine, Pennsylvania State University, and beginning in 1980, she trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Dr. Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology.
Member of the Nominating/Corporate Governance Committee
Member of the Audit Committee
WE NEED GRANT PICKERING BACK, NOT
LMAO
Just being funny
but ya never know.
Be safe brother!
All who took mrna vaccine going to be
really messed up & die a horrible death
New study from Sweden suggests, Pfizer mRNA does indeed integrate into our DNA
https://www.riotimesonline.com/brazil-news/modern-day-censorship/new-study-from-sweden-says-pfizer-mrna-does-indeed-integrate-into-your-dna/
This means that a shot of the Pfizer vaccine, taken even once, could permanently change the DNA of affected cells.
https://www.riotimesonline.com/wp-content/uploads/2022/02/Pfizer-RNA-into-DNA.pdf
Put that in the press & smoke it
Eat more protein
LOL
SHIVSF162P3, ARP-6526, contributed by Drs. Janet Harouse, Cecilia Cheng-Mayer, Ranajit Pal and the DAIDS, NIAID; and mAb 2F5 (ARP-1475). Dr. Susan Zolla-Pazner kindly provided mAb 98.6.
Search 8 grants from Janet Harouse
New York Blood Center, New York, NY, United States
https://grantome.com/grant/NIH/U19-HD048957-01-2
NYU
https://www.researchgate.net/profile/Janet-Harouse
Cecilia Cheng-Mayer's research while affiliated with The Rockefeller University and other places
https://www.researchgate.net/scientific-contributions/Cecilia-Cheng-Mayer-2112538815
grants
https://grantome.com/grant/NIH/R01-CA072822-12
Aaron Diamond AIDS Research Center
New York, United States
https://loop.frontiersin.org/people/23209/bio
Ranajit Pal's research while affiliated with Advanced BioScience Laboratories Inc. and other places
https://www.researchgate.net/scientific-contributions/Ranajit-Pal-38758408
Susan Zolla-Pazner
https://en.wikipedia.org/wiki/Susan_Zolla-Pazner#:~:text=In%20the%20early%20days%20of,cells%20of%20HIV%2Dinfected%20individuals.
Zolla-Pazner Laboratory
https://labs.icahn.mssm.edu/zolla-paznerlab/
The Army-led Thai HIV vaccine efficacy trial, known as RV144, tested the “prime-boost” combination of two vaccines:
https://www.hivresearch.org/hiv-research/rv144#:~:text=The%20Army%2Dled%20Thai%20HIV,that%20commonly%20circulate%20in%20Thailand.
We thank Dr. Kathy Brasky (Texas Biomed/SNPRC) for overseeing the primate study
https://www.txbiomed.org/scientists/kathleen-m-brasky/
https://www.linkedin.com/in/kathleen-brasky-85948a44
We also thank Dr. Mario Roederer, Vaccine Research Center, for the gift of polyclonal IgG purified from SHIV-infected RMs.
Barrack lol
https://www.flowjo.com/about/company/founders
Bethesda, Maryland
https://irp.nih.gov/pi/mario-roederer
Patents by Inventor Mario Roederer
https://patents.justia.com/inventor/mario-roederer
Neutralizing antibodies to HIV-1 and their use
Patent number: 10035845
Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
Type: Grant
Filed: July 27, 2017
Date of Patent: July 31, 2018
Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Washington
Inventors: John Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, William Schief
& gp41 18 more times including John R. Mascola
https://www.linkedin.com/in/mario-roederer-a957a946?challengeId=AQF9sBRUMNaHvgAAAX-ATem7mwS0vbMEh23mUrw-JYM247XVX4zumc_P6GgC29ha3vdF-8ga0nv0MsRbyPTjiieD_Cyh-OyFvA&submissionId=e7affecc-84c3-db16-dc44-c8907ec3923e
Others viewed
Thomas Liechti
Postdoctoral Research Fellow at the Vaccine Research Center, National Institutes of Health
Bethesda, Maryland, United States
Education
University of Zurich University of Zurich Graphic
University of Zurich
Doctor of Philosophy (Ph.D.)Microbiology and Immunology
2011 - 2017
Multicolor flow cytometry phenotyping of B cells in HIV-1 infection; Establishing multicolor flow cytometry panels with up to 16 markers, Multidimensional single cell analysis with dimensionality reduction (t-SNE) and cluster identification (SPADE, Citrus) algorithms, Working with human pathogens in Biosafety level 3 environment, Establishing Luminex assays to analyze antibody responses against different HIV-1 derived proteins/peptides and different IgG isotypes contributing to binding activity
University of Bern (Official)University of Bern (Official) Graphic
University of Bern (Official)
Master of Science (M.Sc.)Microbiology and Immunology
2009 - 2011
I studied the function of surface IgD on neutrophils and basophils on the impact on allergy during my master thesis at the Institute of Immunology of the University Hospital Inselspital Bern under the supervision of Prof. Dr. Clemens Dahinden. The techniques included isolation of basophils and neutrophils, multicolor flow cytometry, ELISA, immune cell stimulation assays and co-cultures.
Hey Ronald, don't make a decision
until you have to, right
but it's not your decision to make
b/c the insiders are going to pay for them
:}
Where did Anthony Fauci go ?
Fox want's to know why he fell of the face of the earth
He's here, Feb 15, 2022
https://www.nbcnews.com/video/fauci-expresses-caution-over-reported-possible-hiv-cure-133249605956
LOL
Perrigo's generics split is back on the docket, thanks to $1.55B Altaris offer
to Altaris Capital Partners for $1.55 billion
https://www.fiercepharma.com/pharma/perrigo-locks-up-buyer-altaris-capital-for-1-5b-prescription-generics-split
Oso Biopharmaceuticals Announces Acquisition of Albuquerque Injectables Business from Catalent Pharma Solutions
Altaris Capital Partners, LLC (“Altaris”), a healthcare investment firm, collaborated with Oso Biopharmaceuticals and provided capital for the transaction.
https://www.biospace.com/article/releases/oso-biopharmaceuticals-announces-acquisition-of-albuquerque-injectables-business-from-catalent-pharma-solutions-/
3M Drug Delivery Systems relaunches as Kindeva Drug Delivery
The deal renews Altaris' interest in biopharma-focused contract ... buy a sterile injectables manufacturing business from Catalent.
https://www.outsourcing-pharma.com/Article/2020/05/04/3M-Drug-Delivery-Systems-relaunches-as-Kindeva-Drug-Delivery
OVERVIEW Zydus Pharmaceuticals (USA) Inc
https://zydususa.com/overview/
Zydus to acquire assets of US-based Nesher Pharmaceuticals
The agreement also encompasses supply and technical services agreements by which certain products of KV Pharmaceuticals will be manufactured by Zynesher Pharmaceuticals, the company said.
https://www.thehindubusinessline.com/companies/zydus-to-acquire-assets-of-us-based-nesher-pharmaceuticals/article23057228.ece
KV Pharmaceutical
It developed bioadhesive drug delivery where molecules adhere to wet sites such as a mucosa (example Clindesse), and is investigating quick-dissolving and controlled-release drug venues.
and in a separate transaction, Dublin, Ireland-based Perrigo Co. acquired Lumara Health’s women’s health care business, including the Clindesse Vaginal Cream, Gynazole-1 and Evamist products, for $82 million.
https://en.wikipedia.org/wiki/KV_Pharmaceutical#cite_note-doyle-4
Perrigo
https://en.wikipedia.org/wiki/Perrigo
Perrigo and Catalent Announce FDA Approval of Perrigo's AB-Rated Generic Version of ProAir® HFA
https://www.perrigo.com/press-release/perrigo-and-catalent-announce-fda-approval-perrigos-ab-rated-generic-version-proairr
Teva filed suit against Perrigo and Catalent
https://www.sec.gov/Archives/edgar/data/818686/000130901414000426/exhibit1.htm
The story of felony & bk additional
Mymetics in demand
In 2009, he took another big leap into a completely new environment and joined the Indian biotechnology company Zydus Cadila as Head of Research, where he conducted excellent development work for 10 years in India.
As head of research at Zydus Cadila, Reinhard has also continued to deepen the collaboration with Swiss TPH. Among other things, he has worked with Swiss TPH on the development of a Leishmania vaccine as part of an EU-funded multinational consortium. More recently, now as head of the Zydus Cadila subsidiary Etna Biotch in Catania, Reinhard has closely involved Swiss TPH in plans to generate new structures for vaccine development in Switzerland.
https://www.myscience.org/news/wire/obituary_dr_reinhard_glueck-2021-swisstph
The Vaccine Technology Centre (VTC) is the vaccine research centre of Zydus Group. VTC has two state-of-the-art R & D Centers, ETNA BIOTECH located in Catania-Italy and the other in Ahmedabad-India.
ETNA BIOTECH is a company whose key competencies lie in researching and developing vaccines and immunotherapeutics for infectious diseases and other chronic illnesses.
Start up of the former Swiss Serum and Vaccine Institute, later Berna Biotech, ETNA BIOTECH is now company of Zydus Cadila, a global healthcare provider and one of the top four pharma companies in India.
https://www.etnabiotech.it/
Etna Biotech srl - Zydus Cadila Research Center
https://www.linkedin.com/company/etna-biotech-srl---zydus-cadila-research-center
https://www.facebook.com/etna.biotech/reviews
Zydus Cadila acquires Etna Biotech, a subsidiary of Crucell N.V.
https://pipelinereview.com/index.php/2008111123298/More-News/Zydus-Cadila-acquires-Etna-Biotech-a-subsidiary-of-Crucell-N.V.html
Executive Summary
Zydus Cadilahas acquired Etna Biotech, a subsidiary of the Dutch biopharmaceutical company Crucell, for an undisclosed sum. Zydus expects the deal to catapult it to the forefront of innovation in vaccine R&D, and is the first acquisition by Zydus of a research firm.
https://medtech.pharmaintelligence.informa.com/SC031613/Zydus-Cadila-acquires-Etna-Biotech
Stegmann says no more moves please :}
Vince Kaiman President at Nesher Pharmaceuticals (USA) LLC
Education
Washington University in St. Louis
https://www.linkedin.com/in/vince-kaiman-18253619
You gotta know that
LOL
Binswanger Named Exclusive Agent for Nesher Pharmaceuticals 89,000 Sq. Ft. Facility in Earth City, Missouri
https://www.yahoo.com/entertainment/news/binswanger-named-exclusive-agent-nesher-144907588.html
https://www.binswanger.com/
Parent Company Zydus Cadila is a global healthcare provider and one of the top five companies in India
https://www.nesher.com/
https://www.nesher.com/index.php/about-us/parent-company
Go figure LOL
Glaxo Wellcome, which helped pay for his computer database, held two trials of different AZT combinations in 1997 and 1998. But only 20 children were in one trial and only 50 in the other, and each time for only six months.
''After that, we had to buy,'' Dr. Duiculescu said. ''We asked if they would donate for the life of the kids, but they said it was not possible. We ask all the companies for discounts or donations. They say 'Not possible.' ''
The Glaxo Wellcome company said that children had been dropped after earlier trials, but that other patients, more recently, were kept on free drugs after trials ended.
Dr. Duiculescu said he was told that he would get part of a $750,000 donation of medicine by Bristol-Myers Squibb for 500 patients, but has not received any yet.
And he said he was interested in a proposed Merck & Company trial of two drugs, Crixivan and Stocrin, but worries that it will contain ''conditions that will be difficult to accept.'' The hospital must buy medicine for one patient for every two the drug company supplies free, ''and I don't think there will be enough money,'' he said.
A Merck spokeswoman, Melinda Hanisch, said the trial would involve only 16 adults and the company was not yet willing to experiment on Romanian children because children's metabolisms are different and the company is ''especially sensitive to ethical concerns.''
Keeping political commitments to fight HIV in France
That will do it, more dirty Hiv Research
https://hivoutcomes.eu/update/hiv-outcomes-organises-a-french-roundtable-delivering-on-political-commitments-to-tackle-hiv-in-france/
Romania Halts AIDS Drug Test
https://www.nytimes.com/1990/10/30/science/romania-halts-aids-drug-test.html
Nicolae Ceausescu, who was overthrown and executed in December 1989
https://www.nytimes.com/2001/01/07/world/romania-s-aids-children-a-lifeline-lost.html
A Dutch charity pays for the drugs for another two. Bristol-Myers Squibb donates drugs for one.
Trial coming brother
Or Moderna & Vir will have to move into pre-clinical after this b/c Dr turn around expert specialist has raised the bar for them on that
LOL
Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform
https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-initiation-phase-1-clinical-trial
CLINICAL CORE
The Clinical Research Core will provide the personnel and administrative support to conduct clinical trials and other clinical research activities related to medical cannabis.
It will leverage Drexel’s clinical expertise and the availability of patients with qualifying conditions for medical cannabis such as, but not limited to, HIV, neuropathies, and PTSD.
The clinical core will launch in early 2022.
https://drexel.edu/cannabis-research/research/projects/
Quality of life in people living with HIV in Romania and Spain
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06567-w
Introducing HIV Outcomes Romania
https://hivoutcomes.eu/introducing-hiv-outcomes-romania/
Members
https://hivoutcomes.eu/about-us/team-members/
Gotta wonder wonder what happened w/ Fruci and Associates, the sec attorney & their mary jane company trip to Swazzyland last month, eh.
Why is Kempers & Stegamnn
doing biz of sorts in Romania, paying taxes ?
Jan Wilschut
Scientific Advisory Board
Drexel University
Romania
https://biography.omicsonline.org/romania/drexel-university/jan-wilschut-1230296
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160090159
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160091622
Fwiw H.C. Wainwright downgraded Grant Pickering's Ettx yesterday
Patents by Inventor Francesco Doro
https://patents.justia.com/inventor/francesco-doro
Senior Scientist - Formulation Development at The Janssen Pharmaceutical Companies of Johnson & Johnson
https://www.arounddeal.com/profile/francesco-doro/t8mdrzvftx/
FORMULATIONS FOR VIROSOMES
Register USPTO Patent
Application Number 16947418
Status Pending
Filing Date 2020-07-31
First Publication Date 2020-11-19
Publication Date 2020-11-19
Owner Janssen Vaccines & Prevention B.V. (Netherlands)
Inventor
Adriaansen, Janik
Doro, Francesco
Abstract
This disclosure provides virosome formulations, in particular, liquid pharmaceutical formulations comprising virosomes.
https://www.onscope.com/ipowner/en/ip/ptus/16947418.html
FORMULATIONS FOR VIROSOMES
Dec 18, 2014 - Crucell Holland B.V.
This disclosure provides virosome formulations, in particular, liquid pharmaceutical formulations comprising virosomes.
https://patents.justia.com/patent/20160317646
Scientific Innovation Manager
OSIVAX
Aug 2021 - Present8 months
Lione, Alvernia-Rodano-Alpi, Francia
GSK
GSK
4 years 9 months
Senior Scientist Drug Product Advanced Technologies
Feb 2020 - Jul 20211 year 6 months
Local representative of the Global DP Advanced Technologies Team: scout and pursue new technologies to improve product and process development.
• Participate in the contract drafting with external companies (in collaboration with BD and Legal depts);
• Scientific and technical monitoring of activities within contract timelines;
• Play a key role in the interface between the external (or internal) collaborators and the Drug Product Development dept.
Senior Scientist Drug Product R&D, Vaccine Discovery Support presso GSK
Nov 2016 - Jan 20203 years 3 months
Siena, Italia
Design and lead vaccine development strategies, from preclinical evidence generation to progress into clinical phases. Define the pre-formulation and formulation development studies for adjuvanted novel vaccine candidates (bacterial and viral recombinant proteins, glycoconjugates). Write source documents for Regulatory documentation. Participate in process definition in close collaboration with the Process Team.
The Janssen Pharmaceutical Companies of Johnson & Johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson
4 years
Senior Scientist - Drug Product Development
Apr 2015 - Oct 20161 year 7 months
Leiden
Formulation Development Scientist
Nov 2012 - Mar 20152 years 5 months
Leiden
I’m responsible for the formulation development of three red carpet projects, from the formulation definition to the selection of the primary packaging.
My main responsibilities are defining the work packages with clear timelines and within a certain budget and managing the scientific workflow within the overall framework of the project.
I manage a team of three people and participate in the recruitment activities.
I’m responsible for lab equipment acquisition.
Novartis Vaccines and Diagnostics
Novartis Vaccines and Diagnostics
8 years
Investigator II
Aug 2010 - Oct 20122 years 3 months
Being part of the Analytics Unit within the Formulation and Delivery Department, I was responsible for analytical methods development for protein and glycoconjugate liquid formulation characterization and stability within four vaccine projects. I had the direct responsibility of an entire vaccine formulation development that I was carrying out with the help of a strongly skilled technician.
As a Project Liaison, I was involved in project advancement at a decisional level, coordinating with…
https://it.linkedin.com/in/francescodoro
Francesco Doro's research while affiliated with Novartis Vaccines and other places
https://www.researchgate.net/scientific-contributions/Francesco-Doro-38583197
OSIVAX
Biotechnology company in Lyon, France
Our Locations
Osivax is based in Lyon, France and Liège, Belgium, two of the premier vaccine R&D clusters in Europe.
Osivax’ mission is to develop universal vaccine candidates designed to provide long-term protection against viruses that mutate rapidly and otherwise require frequent and costly seasonal updates.
Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study
Our Investors
Bpifrance
Right Vincent, now about Bristol Myers Squibb ?
https://osivax.com/news/
Feb 1, 2022
Today we have included our 500th participant as part of our clinical trial operations on OVX836 flu vaccine!
Today we have included our 500th participant as part of our clinical trial operations on OVX836 flu vaccine! Osivax is proud to share this milestone and celebrate the commitment of its clinical team and partners. We’d also like to thank all study volunteers who make it possible.
— Osivax (@OsivaxVaccines) February 1, 2022
Still so dirty Hiv research ?
Buy a COVID vaccine, get an HIV vaccine for free?
https://fortune.com/2021/04/06/basic-research-funding-covid-vaccine/
The preliminary results for an experimental HIV vaccine centered on a protein called eOD-GT8 were released back in February by IAVI, a nonprofit drug developer. They appear to have gone little-noticed by the public before a wildly viral tweet from health advocate Dr. Ayoade Alakija this week.
WOW 😳 New HIV vaccine with a 97% antibody response rate in phase I human trials. This is the most effective trial HIV vaccine to date. It is based on the Moderna's COVID vaccine. COVID tech acceleration could change Rx for cancer & HIV in future. https://t.co/3Nl0UJj6xW
— Dr. Ayoade Alakija (@yodifiji) April 4, 2021
Vaccine maker plans massive investment in plant near BWI in Maryland to produce even more therapies
This is a Catalent manufacturing plant, where officials plan to announce a $230 million expansion Tuesday to their “suites,” or lines, where small amounts of the most advanced medical therapies are produced for some of the biggest pharmaceutical companies.
New Jersey-based Catalent is one of the largest so-called contract development and manufacturing organizations. Its specialty plants are normally unknown to consumers but are gaining attention during the coronavirus pandemic because vaccine makers have outsourced production of billions of doses of their products to them.
Catalent makes vaccines too, but this site focuses on cell and gene therapies, a fast-growing field that promises a host of advanced treatments and cures for some of the worst diseases.
https://www.baltimoresun.com/health/bs-hs-catalent-expanding-gene-therapy-production-20211026-w5435lrpijaeratgb24mx3vvnu-story.html
Dr. Ted Dawson, director of the Institute for Cell Engineering at Johns Hopkins Medicine, said the promise of such therapies is huge, treating everything from rare cancers to loss of vision, though many treatments remain many years off.
The most advanced gene therapies use cells altered in a lab that can fix or replace defective genes. They are sent into someone’s body on those inactivated viruses. The virus can no longer make someone sick but understands how to enter human cells, where the treatments work to alleviate symptoms, cure disease or prevent disease from ever developing.
Dawson works directly on cell therapies for Parkinson’s disease and consults for a gene therapy company investigating an HIV treatment. Others are working on treatments for blindness, sickle cell anemia and other genetic disorders.
“As more therapies become approved there is going to be a need for more capacity to make them,” Dawson said. “Like with COVID-19 vaccines, it took quite a while to scale up to capacity. If there is some revolutionary gene therapy or cell replacement therapy for a common disorder, one would need to scale up for that.”
He said it’s impossible to say how fast manufacturing capacity will be needed, noting that progress on therapies is often slower than the public wants. Further, the steps to ensure safety in production are critical. Manufacturing sites have to follow extremely strict requirements from the FDA.
https://www.fiercepharma.com/manufacturing/catalent-completes-10m-expansion-at-u-s-and-u-k-production-sites
Catalent completes $10M expansion at US and UK production sites
facial nerve paralysis, are no longer a concern
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164361977
U19AI142636
Other Supporting Projects
R01DE023049
https://reporter.nih.gov/search/K-ztMzgyCk25GZC9F4Nb-A/publications?sort_field=pub_year&sort_order=desc
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?
https://reporter.nih.gov/search/K-ztMzgyCk25GZC9F4Nb-A/publications/project-details/9084260
Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420805/
Ref 30. Song RJ, Chenine AL, Rasmussen RA, Ruprecht
https://pubmed.ncbi.nlm.nih.gov/16912320/
Rasmussen RA
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168025818
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168026108
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168026226
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168026314
Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env
R J Song 1, A-L Chenine, R A Rasmussen, C R Ruprecht, S Mirshahidi, R D Grisson, W Xu, J B Whitney, L M Goins, H Ong, P-L Li, E Shai-Kobiler, T Wang, C M McCann, H Zhang, C Wood, C Kankasa, W E Secor, H M McClure, E Strobert, J G Else, R M Ruprecht
Affiliation\
1Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Rasmussen RA
https://pubmed.ncbi.nlm.nih.gov/?term=Rasmussen+RA&cauthor_id=16912320
Hey Bro
I know you didn't think Hiv was the the thing here but I did
What do you think he has to negotiate w/ now ?
Congrats on life friend
:}
@ least they didn't
trade on it
:}
Praying for you brother & all that comes w/ that
If anyone is deserving of a Noble
It's Ruth & Moragne & others that I won't mention
You know what I think about Harvard....!!!!
& if I want to make this about my ego
I WILL
but someone is going to pay the piper
Where the insiders go, we go
So stick that up the next filing / filling
:}
Second link
Vaccine protection by virosome-induced IgG and IgA parallels the cooperation between systemically administered IgG1 and mucosally applied dimeric IgA2 monoclonal antibodies that as single-agents provided no/low protection – but when combined, prevented mucosal SHIV transmission in all passively immunized RMs.
Furthermore, subunit vaccine administration has often involved a single parenteral route (9–11) or sometimes by single mucosal administration (12, 13), but rarely involved combined mucosal and intramuscular (i.m.) immunizations as was done with virosomal vaccines (14, 15). Our team and others have postulated that an effective HIV/AIDS vaccine must be capable of eliciting both systemic and mucosal immune protection for maximal protection of different mucosal portals of entry. However, due to the compartmentalized mucosal and systemic immune systems, the induction of strong immune responses in various local and distant mucosal tissues and in the systemic compartment is challenging. The traditional parenteral immunization involving the i.m. or subcutaneous (s.c.) routes can elicit circulating B and T cells that generally remain mostly in the periphery.
The approach of an HIV vaccine immunization regimen combining the classical i.m. immunization route with mucosal boosting using the intranasal (i.n.) route was proposed as an alternative to induce systemic as well as mucosal anti-HIV immunity. This notably different vaccine strategy was evaluated with unadjuvanted influenza virus-based virosomes displaying HIV gp41 antigens; vaccine-induced systemic and mucosal antibody (Ab) responses were assessed in Chinese-origin rhesus macaques (RMs) that were immunized via two routes followed by intravaginal simian-human immunodeficiency virus (SHIV) challenges (14). The gp41 antigens were derived from Env regions highly conserved across multiple HIV clades and strains (Figure 1). These virosomes are lipid-based particles reconstituted in vitro from influenza viruses but devoid of nucleic acids and thus non-infectious (Figure 2). One population of virosomes was assembled to display on their surface Peptide 1 (P1), an extended version of the Membrane Proximal External Region (MPER) of HIV gp41, to generate virosome-P1. Another virosome population displayed recombinant, truncated gp41 (virosome-rgp41); rgp41 is devoid of the immunodominant region that contains the KLIC motif as well as other domains homologous to human host proteins. The combined vaccine preparation that consists of virosome-P1 plus virosome-rgp41, is termed MYM-V201 (Figure 2).
The initial study in Chinese-origin RMs evaluated only the combination of virosome-P1 plus virosome-rgp41 (but not single-agent virosomes). Control RMs received placebo virosomes devoid of HIV gp41 antigens (14), and two groups of vaccinees were given either four i.m. immunizations or two i.m. immunizations followed by two i.n. boosts, respectively. All animals were challenged intravaginally by repeated low-dose exposures to SHIVSF162P3, an R5-tropic, tier 2, clade B strain; the challenge SHIV encoded a heterologous gp41 sequence compared to that in the immunogens. Priming via the i.m. route followed by i.n. boosting was remarkably effective: 100% of the animals were protected and did not seroconvert to SIV Gag, a viral protein absent in the vaccine. However, protection was not sterile as some animals had low-level viral RNA blips just at the limit of detection (14).
Here we report a repeat study performed in Indian-origin RMs conducted at a different animal facility with the combination of unadjuvanted virosomes-P1 plus virosomes-rgp41, termed MYM-V201, using repeat low-dose intravaginal challenges. We included an additional group to evaluate animals vaccinated with the single-agent unadjuvanted virosomes-P1. The rationale for including the latter group is the successful conclusion of a Phase 1 clinical study with virosomes-P1 in low-risk women (15), where this vaccine was safe and immunogenic. However, no efficacy data existed from NHP studies regarding virosome-P1 as single immunogen.
The current study demonstrated significant protection for the combination of virosomes-P1 plus virosomes-rgp41 that – depending on the read-out – ranged from 78% to 87% during the first SHIV challenge phase, i.e., challenges #1 to #7, up to the day of but not including challenge #8 (termed Challenge Phase I). However, when the SHIV inoculum was increased by 50% as in the earlier study in Chinese RMs (14), protection was lost. Single-agent virosomes-P1 showed no efficacy throughout both SHIV challenge phases. We conclude that the combination of the two HIV gp41 virosomes, virosomes-P1 plus virosomes-rgp41, was safe, immunogenic, and effective as long as the intravaginal SHIV inoculum was within a 100-fold excess over the HIV RNA levels found in the semen of acutely infected men (16), or within a 70,000-fold excess of the median semen viral RNA content men who were part of HIV discordant heterosexual couples (17).
However, by Fc array analysis, protection in Group L was significantly associated with increased Fc?R2/3(A/B) across several time points compared to control Group M; iii) protection in Group L was lost in Challenge Phase II when the virus inoculum was increased by 50%; iv) estimates of the SHIV challenge inoculum in comparison with vRNA levels founds in the semen of men with acute HIV infection indicated protection against intravaginal challenge in the Indian RMs was at a high level as long as the SHIV inoculum did not exceed HIV RNA levels in semen of men with acute HIV infection by >100 fold (16); and v) single-agent virosomes-P1 provided no protection throughout Challenge Phases I and II and thus cannot be considered for clinical development. Importantly – during Challenge Phase I – we have confirmed that the combination of virosomes-P1 plus virosomes-rgp41 protects significantly against intravaginal SHIV challenges. Thus, the safety and efficacy of the gp41 virosomal platform, described earlier for Chinese-origin RMs, has been confirmed in Indian macaques.
Thus the Morgane reads I first posted & the Catalnet patent ref
P1 Rgp41
Aperipheral blood mononuclear cell (PBMC) is any blood cell having a round nucleus such as lymphocyte, monocyteor amacrophage. These blood cells are a critical component in theimmune systemto fight infection and adapt to intruders.
https://en.wikipedia.org/wiki/Peripheral_blood_mononuclear_cell
It's not the cell line that matters to me b/c all the majors have them. Accumulation in the below....!!! What matters to me is what Ruth & crew are doing w/ that, right ?
THE FINISH LINE....!!!!!
Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection
https://journals.lww.com/aidsonline/Fulltext/2021/12010/Mucosal_AIDS_virus_transmission_is_enhanced_by.2.aspx
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
They have it down to a single cell, the point of entry ? First line of defense....!!!!!!
Well above my pay grade but they didn't want us having that & it's not my ego here, the insiders won't take a deal that isn't right for them b/c they will just wait. Just might be the lucky place for them & us being a Nobel for Ruth b/c she couldn't have know that Alum would fail or did she ?
That is some deep chit friend & thanks for all you help over the years but no need in begging for something even close to what was thrown @ Vir B in Jan 2022
:}
Something Hiv must be happening in 2022
lol
https://www.vir.bio/pipeline/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167270024
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157819849
https://www.vir.bio/pipeline/
https://www.idimmunotherapy.com/speakers-corti.php
& University of Milan
https://ch.linkedin.com/in/davide-corti-99421640
Leaving Mymx a Ceo w/ the charisma of a lizard
Come on Ronnie, gist us
LMAO
5 Humabs BioMed, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland
Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges
Siqi Gong1,2†, Samir K. Lakhashe1†, Dinesh Hariraju1,2†, Hanna Scinto1,3, Antonio Lanzavecchia4,5, Elisabetta Cameroni4,5, Davide Corti4,5, Sarah J. Ratcliffe6, Kenneth A. Rogers2,7, Peng Xiao2, Jane Fontenot2, François Villinger2,7 and Ruth M. Ruprecht1,2,3,7*
1Texas Biomedical Research Institute, San Antonio, TX, United States
2New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States
3Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health San Antonio, San Antonio, TX, United States
4Institute for Research in Biomedicine, Bellinzona, Switzerland
5Humabs BioMed, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland
6University of Pennsylvania, Philadelphia, PA, United States
7Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States
https://www.frontiersin.org/articles/10.3389/fimmu.2021.705592/full
Look familiar folks
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168019601
Vir to extend COVID-19 treatment approach to HIV, malaria with $50M from Gates Foundation
https://www.geekwire.com/2022/vir-to-extend-covid-19-treatment-approach-to-hiv-malaria-with-50m-from-gates-foundation/
Bishal Marasini
https://www.linkedin.com/in/bishal-marasini-a6579888
https://www.researchgate.net/profile/Bishal-Marasini
A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques
https://journals.asm.org/doi/10.1128/jvi.01884-19?permanently=true&
TWEETED BY 3
https://wolterskluwer.altmetric.com/details/111946009/twitter
Supplemental Digital Content for
Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection
*Correspondence to: ruth.ruprecht@louisiana.edu
Current address: S.K.L.: University of Texas MD Anderson Cancer Center, Houston, TX
A.A.: Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA
Fig. S3. A3R5.7 cell line-based neutralization assay of the two macaques selected as IgG donors for the enSHIVIG prep. Polyclonal IgG was purified from sera of donor macaques at the time points post-infection indicated. The macaques were in the early stages of SHIV-2873Nip [2] infection. (a and b) Neutralization assays were performed using A3R5.7 cells with the reporter virus NL-LucR.1157ipd3N4 (see Fig. S1 legend). The assay was terminated after 48 h and bioluminescence was read.
Fig. S4. A3R5.7 cell line-based neutralization assay. Polyclonal IgG was purified from donor macaques at the time points post-infection indicated. The macaques were in the early stages of infection with SHIV-2873Nip [2]. (a-f) Neutralization assays were performed using A3R5.7 cells with the reporter virus NL-LucR.1157ipd3N4 as described in the legend for Fig. S3
Fig. S6. Pharmacokinetic study. Three rhesus macaques were treated intravenously (i.v.) with different doses of enSHIVIG. Serum samples were collected, and enSHIVIG concentrations were measured by ELISA binding to HIV-C gp120. IgG was isolated from serum samples and C’-ADE assays were performed. Negative neutralization indicates enhancement. The assays were performed at 24 h after enSHIVIG administration, a time point chosen based upon our earlier data [5]; *for animal 33174, only insufficient IgG amounts could be recovered from the 24 h time point; the value given shows C’-ADE at 12 h post treatment.
enSHIVIG bound significantly better to gp160 or gp140 (Fig. 2d,e) than to gp120 (Fig. 2c), implying predominant binding to gp41.
These data imply that C’-ADE was predominantly due to the action of anti-gp41 antibodies present as the major fraction in enSHIVIG; other investigators have identified antibodies against the immunodominant HIV gp41 region as responsible for ADE in vitro
Thus, well characterized mAbs are unpredictable in their interactions with different HIV strains. Enhancing antibodies have also been implicated in mother-to-child transmission of HIV in a number of studies [42–44]; some reports raised the possibility that enhancement may be linked to antibodies targeting HIV-1 gp41 [
AIDS vaccine development should consider the potential of ADE-VA due to vaccine-induced antibodies during experimental vaccine trials. To rule out this possibility, passive immunization with vaccine-induced antibodies could be used as a tool in biologically relevant animal models, that is, models that reflect key aspects of HIV transmission among humans, including i) tier 2 R5 challenge viruses carrying HIV-1 Env, ii) a nonhuman primate species, and iii) antibodies that are heterologous to the challenge viruses. The latter point is important since matched homologous virus/antibody systems will exaggerate neutralization and thereby mask potential enhancement by weakly or non-neutralizing antibodies. In the realistic setting of human vaccinees’ exposure to circulating HIV strains, an exact match between immunogen composition and the myriad of HIV quasispecies can never be expected.
Indirect evidence that vaccine-induced antibodies can have adverse effects comes from a feline immunodeficiency virus (FIV) study, where cats were vaccinated with various recombinant envelope glycoproteins [46]. Although neutralization in cell-line based assays was observed in plasma samples from some vaccinated groups, no virus-neutralizing antibodies were detected in the feline lymphocyte assay. Upon FIV challenge, cell-associated FIV loads were increased in the groups vaccinated with recombinant FIV Env glycoproteins compared to other groups or controls. Passive transfer of unfractionated plasma from groups with increased cell-associated FIV enhanced viral infection parameters in the recipients. While these data imply ADE, an influence of other factor(s) present in unfractionated plasma cannot be ruled out.
In sum, AIDS virus C’-ADE is real – as our passive immunization showed significant lowering of the virus dose needed to achieve viremia indicative of ADE-VA. As such, the current study with early-stage enSHIVIG confirmed our unexpected finding with late-stage SHIVIG, selected for maximal in-vitro tier 2 SHIV cross-neutralization, where low-dose pretreatment yielded sub-neutralizing anti-HIV Env IgG levels that significantly increased the number of transmitted viral quasispecies. Together, our data imply that decreasing anti-HIV Env neutralizing antibody titers could bring vaccinated individuals into a situation where ADE-VA prevails.
ADE-VA may be of concern for other pathogens, especially rapidly mutating RNA viruses susceptible to neutralization escape. Vaccine development will need to consider potential enhancement of host susceptibility to infection due to ADE [47,48]. We propose that our strategy – passive immunization with purified polyclonal IgG isolated from previously infected/vaccinated individuals, combined with in-vivo end-point virus titration to assess the amount of virus needed to achieve infection of naïve versus passively immunized animals, can play an important role in assessing the potential for ADE-VA.
Robert J Mclinden U.S. Military HIV Research Program
https://www.researchgate.net/profile/Robert-Mclinden
https://www.researchgate.net/institution/US_Military_HIV_Research_Program
https://www.linkedin.com/in/robert-mclinden-9b15373
A3R5.7 Cells
https://www.hivreagentprogram.org/Catalog/HRPCellLines/ARP-12386.aspx
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0077756
Overall, we screened eight SHIV-infected monkeys and selected the two with the highest enhancement in the absence of neutralization in human PBMC assays, animals RKu-12 and RPm-12; data for the entire macaque cohort, including assays for enhancement/neutralization of SHIV-1157ipd3N4 until week 106 post-inoculation in A3R5.7 cells
The DOE & DOD baby
GET WOKE
LOL
Wayne A. Marasco, MD, PhD
https://www.dana-farber.org/find-a-doctor/wayne-a-marasco/
mAb Fm-6-IgG1 by W.A. Marasco (Dana-Farber Cancer Institute)
Dr. Shiu-Lok Hu
https://sop.washington.edu/people/shiu-lok-hu/
which later became a part of the Bristol-Myers Squibb Pharmaceutical Research Institute. During this time (1985-1997), he developed the first recombinant virus as a candidate HIV vaccine for FDA-approved clinical trials and provided the first demonstration of vaccine protection against SIV infection in a macaque model by the “poxvirus prime-protein boost” immunization strategy.
Courses Taught
Pharmaceutics 533: Biopharmaceutics and Drug Delivery
gp120 and gp160 by S.L. Hu (University of Washington)
https://www.hivreagentprogram.org/
HIV-1MN gp41, consensus-clade C peptides, and CN54 gp140 [24] by the NIH AIDS Reagent Program
https://web.expasy.org/cellosaurus/CVCL_S540
Category Cancer cell line
A3R5.7 cells by D.C. Montefiori (Duke University
Conclusion:
These passive immunization data give proof of IgG-mediated enhanced virus acquisition after mucosal exposure – a potential concern for antibody-based AIDS vaccine development.
Discussion
Here we showed: i) enSHIVIG, when passively administered to macaques, enhanced virus acquisition and significantly lowered the amount of virus needed to achieve viremia compared to naive controls; ii) ex-vivo enSHIVIG testing in the presence of active complement revealed significant C’-ADE activity that was abrogated by C’ heat inactivation or anti-CD21 mAb. These results indicate that antibodies generated during early-stage HIV/SHIV infection may increase host susceptibility and facilitate virus acquisition and early dissemination.
Previously [21], we had treated macaques biweekly with different intravenous doses of SHIVIG, the polyclonal high-titer neutralizing IgG, in order to link in-vitro neutralization titers with prevention of mucosal SHIV acquisition. Unexpectedly, animals pretreated with low-dose SHIVIG (25 mg/kg) had more viral quasispecies compared to untreated controls – implying increased SHIV transmission. Despite good SHIVIG neutralizing activity in TZM-bl cells, enhancement was observed in the presence of active complement in CR2/CD21-expressing SupT1.R5 cells that was abrogated by complement heat inactivation [21]. Together, these findings reinforce our current data that weakly or non-neutralizing neutralizing IgG may enhance mucosal SHIV acquisition through mechanisms dependent on complement activation.
It is intriguing to compare the 3.4-fold enhanced mucosal SHIV-1157ipd3N4 acquisition we report here with the magnitude of in-vitro HIV enhancement by Willey et al.[18] who measured C’-ADE in CR2-expressing SupT1/R5 cells using paired autologous early-stage sera/HIV isolates. Enhancement ranged from 8- to 236-fold and was lower when assessed with heterologous virus isolates. Differences in the order-of-magnitude of HIV C’-ADE reported [18] and our 3.4-fold lowering of the SHIV challenge dose needed to persistently infect enSHIVIG-pretreated macaques can be ascribed to CR2 expression by all SupT1.R5 cells used for in-vitro assays. In vivo, however, CR2 is expressed only by select cell populations, such as B cells, follicular dendritic cells, and according to a recent report [33], on naive CD4+ and CD8+ T cells.
In addition to C’-ADE, in-vitro assays have revealed another mechanism: Fc receptor-mediated ADE (FcR-ADE) [11,13,34–37] (reviewed in [38,39]). Monocyte/macrophage-derived cell lines expressing different FcRs were used to demonstrate FcR-ADE. Forthal et al.[40] provided indirect evidence of FcR-ADE from a Phase III AIDS vaccine trial; by subgroup analysis, a statistically significant association was noted between increased HIV acquisition and the Fc?RIIIa allele in vaccinees given monomeric gp120.
Our present data as well as those summarized above from prior studies have one common denominator: the IgGs were polyclonal. As such, we cannot distinguish between two possibilities for ADE: i) polyclonal IgG consists of a mixture inherently neutralizing and inherently enhancing antibodies; and ii) a given IgG neutralizes in one situation and enhances in another. This key issue can only be addressed by using mAbs – done in a seminal study by Kliks et al.[41] who examined the interaction of two different human anti-V3 mAbs with three different HIV-1 strains. Depending on the virus tested, the results yielded either neutralization, enhancement, or neither. Thus, well characterized mAbs are unpredictable in their interactions with different HIV strains. Enhancing antibodies have also been implicated in mother-to-child transmission of HIV in a number of studies [42–44]; some reports raised the possibility that enhancement may be linked to antibodies targeting HIV-1 gp41 [43–45].
Although different investigators have shown HIV ADE in various cell line-based assays over the years, whether such in-vitro data would translate into Antibody-Dependent Enhanced Virus Acquisition – ADE-VA – remained unsolved. Passive immunization of macaques with early-stage anti-SHIV IgG followed by intrarectal SHIV challenge gave proof-of-principle for increased virus acquisition and host susceptibility. AIDS vaccine development should consider the potential of ADE-VA due to vaccine-induced antibodies during experimental vaccine trials. To rule out this possibility, passive immunization with vaccine-induced antibodies could be used as a tool in biologically relevant animal models, that is, models that reflect key aspects of HIV transmission among humans, including i) tier 2 R5 challenge viruses carrying HIV-1 Env, ii) a nonhuman primate species, and iii) antibodies that are heterologous to the challenge viruses. The latter point is important since matched homologous virus/antibody systems will exaggerate neutralization and thereby mask potential enhancement by weakly or non-neutralizing antibodies. In the realistic setting of human vaccinees’ exposure to circulating HIV strains, an exact match between immunogen composition and the myriad of HIV quasispecies can never be expected.
Indirect evidence that vaccine-induced antibodies can have adverse effects comes from a feline immunodeficiency virus (FIV) study, where cats were vaccinated with various recombinant envelope glycoproteins [46]. Although neutralization in cell-line based assays was observed in plasma samples from some vaccinated groups, no virus-neutralizing antibodies were detected in the feline lymphocyte assay. Upon FIV challenge, cell-associated FIV loads were increased in the groups vaccinated with recombinant FIV Env glycoproteins compared to other groups or controls. Passive transfer of unfractionated plasma from groups with increased cell-associated FIV enhanced viral infection parameters in the recipients. While these data imply ADE, an influence of other factor(s) present in unfractionated plasma cannot be ruled out.
In sum, AIDS virus C’-ADE is real – as our passive immunization showed significant lowering of the virus dose needed to achieve viremia indicative of ADE-VA. As such, the current study with early-stage enSHIVIG confirmed our unexpected finding with late-stage SHIVIG, selected for maximal in-vitro tier 2 SHIV cross-neutralization, where low-dose pretreatment yielded sub-neutralizing anti-HIV Env IgG levels that significantly increased the number of transmitted viral quasispecies. Together, our data imply that decreasing anti-HIV Env neutralizing antibody titers could bring vaccinated individuals into a situation where ADE-VA prevails.
ADE-VA may be of concern for other pathogens, especially rapidly mutating RNA viruses susceptible to neutralization escape. Vaccine development will need to consider potential enhancement of host susceptibility to infection due to ADE [47,48]. We propose that our strategy – passive immunization with purified polyclonal IgG isolated from previously infected/vaccinated individuals, combined with in-vivo end-point virus titration to assess the amount of virus needed to achieve infection of naïve versus passively immunized animals, can play an important role in assessing the potential for ADE-VA.
https://www.uab.edu/medicine/gastroenterology/research/mhic/investigators/23-centers/mhic/76-christina-ochsenbauer-jambor-phd
Christina Ochsenbauer-Jambor, Ph.D.
Dr. Ochsenbauer-Jambor completed her undergraduate studies in biology at the Johann-Wolfgang-Goethe Universität, Frankfurt am Main in Germany in 1988. She then moved to the Ruprecht-Karls-Universität in Heidelberg, Germany, where she studied molecular biology (virology) and zoology (primate ethology) and earned her ‘Diplom’ (Master) of Biology (magna cum laude) in 1992. Her Master’s thesis focused on functions of the HIV-1 Env protein, with the work performed at the German Cancer Research Center (DKFZ) in Heidelberg. After completing her Ph.D. thesis entitled “Investigations concerning the function of the HIV-1 Vif protein: Generation of a cell-culture model system by using selectable, replication-competent HIV-1” at the DKFZ, she received her Ph.D. (magna cum laude) in virology and molecular biology from Ruprecht-Karls-Universität in 1996. During her undergraduate and graduate work, Dr. Ochsenbauer-Jambor was a recipient of two scholarships from the German National Merit Fundation. After postdoctoral fellowship (1996-2001) in retroviral glycoprotein intracellular trafficking in the Department of Microbiology at UAB, she joined the UAB faculty in 2002 as a Research Instructor in the same department. In 2003, she relocated to the Department of Medicine, Division of Hematology/ Oncology.
Dr. Ochsenbauer-Jambor investigates the role of DC-SIGN in the capture and trans-infection of HIV-1 with special emphasis on virion internalization pathways and the acquisition of selective DC-SIGN-dependent resistance to neutralizing antibodies.
Patents by Inventor James Hoxie
https://patents.justia.com/inventor/james-hoxie
For sNef blocking, mouse anti-Nef EH1mAb (1 µg/mL, kindly provided by Dr James Hoxie
https://academic.oup.com/jid/article/211/8/1229/916369
Montreal 69
http://loop-impact.frontiersin.org/impact/article/788619#demographics
James A. Hoxie, M.D.
Perelman School of Medicine
University of Pennsylvania
https://www.med.upenn.edu/apps/faculty/index.php/g275/p10334
https://cfar.duke.edu/about/advisory-board
https://www.researchgate.net/scientific-contributions/James-A-Hoxie-38693762
Stanley Alan Plotkin
https://www.med.upenn.edu/apps/faculty/index.php/g275/p1554
ADE-VA may be of concern for other pathogens, especially rapidly mutating RNA viruses susceptible to neutralization escape. Vaccine development will need to consider potential enhancement of host susceptibility to infection due to ADE [47,48]. We propose that our strategy – passive immunization with purified polyclonal IgG isolated from previously infected/vaccinated individuals, combined with in-vivo end-point virus titration to assess the amount of virus needed to achieve infection of naïve versus passively immunized animals, can play an important role in assessing the potential for ADE-VA.
Acknowledgements
We thank F. Villinger and S. Gong (UL Lafayette/NIRC) for critical reading of the manuscript; A. Gray and E. Plake (Texas Biomed) for assistance with in vitro assays, J. Hoxie (University of Pennsylvania) for providing the SupT1.R5 cell line, C. Ochsenbauer (University of Alabama, Birmingham) for plasmid pNL-LucR.T2A. We thank K. Brasky and P. Frost for coordinating the primate studies and S. Joubran for assistance with the preparation of the manuscript. The following reagents were obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: HIV-1MN gp41 recombinant protein made in E. coli, ARP-12027 (contributed by DAIDS/NIAID; produced by ImmunoDX, LLC); recombinant HIV-1 CN54 gp140 from CHO cells, ARP-12064 (contributed by DAIDS/NIAID; produced by Polymun Scientific, Inc.).
Funding: This work was supported by NIH grants R01 DE023049 and U19 AI142636 to R.M.R.
https://www.google.com/search?q=R01+DE023049&oq=R01+DE023049&aqs=edge..69i57.1333j0j4&sourceid=chrome&ie=UTF-8
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
https://grantome.com/grant/NIH/U19-AI142636-01